Pharma giant Glenmark announced the launch of its nitric oxide nasal spray (NONS) on Wednesday. This nasal spray will be used for the treatment of Covid-19 in adult patients, who are considered to be at the high risk of disease progression.
Once this medicine is sprayed over the nasal mucosa, it acts as a barrier against the virus and prevents the infection from entering into the lungs.
It has been mentioned that the company has received the marketing and manufacturing approval from the Drugs Controller General of India for "FabiSpray".
Dr Monika Tandon, Senior VP & Head - Clinical Development, Glenmark Pharmaceuticals Ltd., commented: "The results from this Phase 3, double-blind, placebo-controlled trial are encouragingIn the Indian market, FabiSpray will be sold in a price of Rs 850 per unit (including GST).
Dr Monika Tandon, Senior VP & Head - Clinical Development, Glenmark Pharmaceuticals Ltd., commented: "The results from this Phase 3, double-blind, placebo-controlled trial are encouraging. Demonstration of reduction in the viral load has a significant positive impact from a patient and community perspective.
In the current scenario, with new emerging variants exhibiting high transmissibility, NONS provides a useful option in India's fight against COVID-19." As per studies conducted in the Utah State University USA, NONS is proven to kill 99.9% of SARS-Cov-2 virus including Alpha, Beta, Gamma, Delta, and Epsilon variants within 2 minutes.
Naselin Anti-Viral nasal spray was launched by Cipla Healthcare last year with Povidone-Iodine which gave production against Covid-19 and other respiratory tract infections.